世界のサイトメガロウイルス網膜炎市場の規模、シェア、傾向分析レポート – 業界の概要と2031年までの予測

サイトメガロウイルス網膜炎市場分析

サイトメガロウイルス（CMV）網膜炎市場は、認知度の高まり、治療オプションの進歩、患者数の増加により、大幅な成長が見込まれています。CMV網膜炎は主に、HIV/AIDS患者や臓器移植患者などの免疫不全患者に影響を与えるため、効果的な治療法の必要性が浮き彫りになっています。市場における最近の動向には、革新的な薬剤処方やジェネリック医薬品の選択肢の拡大などがあり、治療へのアクセス性と手頃な価格が向上しています。F.ホフマン・ラ・ロシュ、ギリアド・サイエンシズ、アイポイント・ファーマシューティカルズなどの主要企業は、有効性の向上と副作用の最小化に重点を置き、新しい治療法を市場に投入するための研究開発に多額の投資を行っています。さらに、製薬会社と医療機関の協力とパートナーシップにより、新しいCMV治療法の開発が促進されています。CMV関連疾患の認知度向上を目的とした政府の取り組みも、市場の成長に貢献しています。医療インフラの継続的な進歩と医療費の増加により、CMV 網膜炎市場は今後数年間で成長することが予想され、患者の転帰の改善と生活の質の向上への期待が生まれます。

サイトメガロウイルス網膜炎市場規模

世界のサイトメガロウイルス網膜炎市場規模は、2023年に1億8,397万米ドルと評価され、2024年から2031年の予測期間中に5.60%のCAGRで成長し、2031年には2億8,449万米ドルに達すると予測されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Researchがまとめた市場レポートには、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

サイトメガロウイルス網膜炎の市場動向

「抗ウイルス療法の採用増加」

The cytomegalovirus (CMV) retinitis market is experiencing significant growth, driven largely by the rising prevalence of immunocompromised populations, particularly among individuals with HIV/AIDS and organ transplant recipients. A prominent trend in this market is the increasing adoption of antiviral therapies, such as ganciclovir and foscarnet, which have proven effective in managing CMV retinitis. For instance, advancements in the formulation of these medications, including the development of intravitreal implants that provide sustained drug release, are enhancing treatment efficacy and patient compliance. Furthermore, the emergence of novel therapeutic options, such as maribavir, is expanding the treatment landscape, offering improved safety profiles and reduced resistance rates. As healthcare providers focus on early diagnosis and timely intervention, the demand for diagnostic tools, such as PCR testing, is also rising. Overall, the cytomegalovirus retinitis market is poised for growth as innovative treatment strategies and increased awareness contribute to better patient outcomes.

Report Scope and Cytomegalovirus Retinitis Market Segmentation   

Cytomegalovirus Retinitis Market Definition

Cytomegalovirus (CMV) retinitis is an ocular disease caused by the cytomegalovirus, a member of the herpesvirus family. It primarily affects individuals with weakened immune systems, such as those living with HIV/AIDS, organ transplant recipients, or patients undergoing immunosuppressive therapies. The condition is characterized by inflammation and damage to the retina, which can lead to vision loss if left untreated. Symptoms may include blurred vision, floaters, and blind spots.

Cytomegalovirus Retinitis Market Dynamics

Drivers

• Increasing Prevalence of Immunocompromised Patients

The increasing prevalence of immunocompromised patients significantly contributes to the rising incidence of cytomegalovirus (CMV) retinitis. Specifically, the surge in HIV/AIDS cases and the growing number of organ transplant recipients have heightened the risk of developing this condition. For instance, data from the Centers for Disease Control and Prevention (CDC) shows that approximately 1.2 million people are living with HIV in the U.S., many of whom are at risk for opportunistic infections such as CMV retinitis. In addition, the Organ Procurement and Transplantation Network (OPTN) reports that 46,632 organ transplants were performed in 2023, reflecting an 8.7% increase from 2022. This growing patient population underscores the urgent need for effective therapies and serves as a significant driver for the CMV retinitis market, as pharmaceutical companies and healthcare providers strive to meet the rising demand for specialized treatments.

• Increase in Elderly Population

The increase in the elderly population is a significant driver of the global cytomegalovirus (CMV) retinitis market. As people age, their immune systems naturally weaken, making them more susceptible to various infections, including CMV. According to the World Health Organization (WHO), the global population aged 60 years and older is projected to reach 2.1 billion by 2050, up from 1 billion in 2020. Such demographic shift is particularly important because CMV retinitis is more prevalent among older adults, especially those with compromised immune systems due to conditions such as diabetes or other chronic diseases. In addition, the CDC highlights that the incidence of CMV retinitis is notably higher in individuals over the age of 40, further emphasizing the growing risk within this age group. This increasing elderly population creates a substantial market driver for the global CMV retinitis market, as healthcare providers and pharmaceutical companies are compelled to focus on developing effective treatment options tailored to this vulnerable demographic.

Opportunities

• Growing Advancements in Drug Development

Advancements in drug development are significantly transforming the landscape of treatment options for cytomegalovirus (CMV) retinitis. Continuous research and development efforts have led to the discovery of new antiviral agents and enhanced drug formulations, improving efficacy and safety profiles. For instance, recent studies have highlighted the development of letermovir, an antiviral agent that has shown promise in preventing CMV infection in transplant recipients, effectively reducing the incidence of CMV-related complications. In addition, ongoing research into combination therapies and long-acting formulations aims to improve patient adherence and outcomes. Such trends offer companies the opportunity to leverage advancements in drug development to introduce more effective and safer treatments, ultimately addressing the growing demand for effective CMV retinitis therapies and positioning themselves advantageously within this expanding market.

• Rising Initiatives to Raise Disease Awareness

Increasing awareness campaigns play a crucial role in enhancing public knowledge about cytomegalovirus (CMV)-related diseases, leading to earlier diagnosis and treatment of conditions such as CMV retinitis. For instance, the Centers for Disease Control and Prevention (CDC) launched the "CMV Awareness Month" campaign, which encourages testing and awareness about the virus, particularly among pregnant women and immunocompromised individuals. By raising awareness through educational programs and outreach efforts, the such aslihood of early diagnosis increases, which is crucial for effective treatment and management of CMV retinitis. Increased awareness about the disease ultimately expands the patient base for CMV retinitis therapies, presenting a significant opportunity for pharmaceutical companies to develop targeted marketing strategies and enhance treatment accessibility.

Restraints/Challenges

• High Treatment Costs for Existing Antiviral Therapies

High treatment costs for existing antiviral therapies for cytomegalovirus (CMV) retinitis represent a significant barrier to accessibility, particularly for patients in low- and middle-income countries. The price of antiviral drugs, such as ganciclovir and foscarnet, can be prohibitively expensive, often placing them out of reach for individuals who lack adequate health insurance or financial resources. Such economic barrier leads to under-treatment and also result in delays in initiating necessary therapy, exacerbating the progression of CMV retinitis and increasing the risk of severe vision loss. Consequently, hampering the overall market development.

• Lack of Skilled Professionals

The lack of skilled professionals poses a significant challenge to the cytomegalovirus (CMV) retinitis market, impacting both diagnosis and treatment outcomes. Effective management of CMV retinitis requires specialized knowledge and expertise, particularly in identifying at-risk populations, interpreting diagnostic tests, and administering appropriate antiviral therapies. However, there is a notable shortage of trained healthcare professionals, including ophthalmologists and infectious disease specialists, particularly in low- and middle-income countries. For instance, the World Health Organization (WHO) estimates a projected shortfall of 10 million health workers by 2030, mostly in low- and lower-middle-income countries. Consequently, shortage of skilled professionals emerges as a significant market challenge, hindering the growth and effectiveness of the CMV retinitis market and compromising patient outcomes.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Cytomegalovirus Retinitis Market Scope

The market is segmented on the basis of eye diseases, drug type, application, treatment, dosage form, and end-users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Eye Diseases

• Glaucoma
• Cataract
• Ocular Hypertension
• Uveitis

Drug Type

• Ganciclovir
• Valganciclovir
• Foscarnet
• Cidofovir
• Others

Application

• Transplantation
• Organ Transplantation
• Congenital CMV Infection

Treatment

• Anti-CMV Oral Ganciclovir
• Anti-CMV Intravenous Drug Therapy
• Anti-CMV Intraocular (Local)
• Anti-HIV Systemic
• Retinal Detachment Through Vitrectomy

Dosage Form

• Capsule
• Implant
• Solution
• Tablet
• Others

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Cytomegalovirus Retinitis Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, eye diseases, drug type, application, treatment, dosage form, and end-usersas referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America holds a dominant position in the market, largely due to the strong presence of several leading manufacturers and extensive research and development activities in the region. The continuous investment in innovative CMV treatments and a high level of healthcare expenditure further support market growth. In addition, robust infrastructure and favorable regulatory frameworks contribute to the region's leadership in advancing CMV-related therapies.

アジア太平洋地域では、予測期間中にさまざまな要因により、サイトメガロウイルス網膜炎市場が堅調に成長しました。CMV網膜炎とその治療法に関する意識を高める政府の取り組みが、この成長に大きく貢献しました。さらに、裕福な患者数の増加と手頃な価格のジェネリック医薬品の入手可能性により、この地域での治療へのアクセスと採用が強化されました。

レポートの国別セクションでは、市場の現在および将来の動向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。下流および上流のバリュー チェーン分析、技術動向、ポーターの 5 つの力の分析、ケース スタディなどのデータ ポイントは、各国の市場シナリオを予測するために使用される指標の一部です。また、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されます。  

サイトメガロウイルス網膜炎の市場シェア

市場競争環境では、競合他社ごとの詳細が提供されます。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などが含まれます。提供される上記のデータ ポイントは、市場に関連する会社の焦点にのみ関連しています。

サイトメガロウイルス網膜炎市場で活動する市場リーダーは次のとおりです。

• F.ホフマン・ラ・ロシュ社（スイス）
• ギリアド・サイエンシズ（米国）
• キメリックス（米国）
• アイオニス・ファーマシューティカルズ（米国）
• アイポイント・ファーマシューティカルズ（米国）
• サノフィ（フランス）
• CSL（米国）
• エムキュア・ファーマシューティカルズ（インド）
• エンド社（アイルランド）
• アムニール・ファーマシューティカルズLLC（米国）
• ファイザー社（米国）

サイトメガロウイルス網膜炎市場の最新動向

• 2022年9月、プロバイオジェンはシティ・オブ・ホープと提携し、AGE1.CR.pIXワクチン製造プラットフォームを活用してサイトメガロウイルス（CMV）ワクチンを開発するための商用ライセンス契約を締結しました。このコラボレーションは、革新的なワクチンソリューションを推進することを目的としており、ウイルス感染に関連する重大な医療課題に取り組むという両組織の取り組みを強調しています。
• Synklinoは2022年6月、慢性ウイルス感染症の治療法開発というミッションをサポートするために、シリーズAの資金調達ラウンドで2,980万ユーロ（約3,180万米ドル）を調達することに成功しました。この投資は主に、サイトメガロウイルス（CMV）治療を標的とする候補薬SYN002の開発に充てられ、この分野で満たされていない重要な医療ニーズに対処するという同社の取り組みをさらに推進します。

SKU-57317